InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,952.00
(
-0.19%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.84
(
0.35%
)
Bitcoin
57,482.47
(
-1.30%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 04/13/2022 4:59:53 AM

Wednesday, April 13, 2022 4:59:53 AM

Post# of 251670
GSK acquires SRRA for $55/sh cash—a 39% premium to yesterday's close:

https://www.businesswire.com/news/home/20220411006012/en/

The nominal deal value is $1.9B.

SRRA's lead asset is Momelotinib, a JAK inhibitor that has passed through many companies (Cytopia, YM Biosciences, GILD, SRRA, and now GSK).

Note: SRRA implented a 1:40 reverse split in Jan 2020.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up